Sökning: "Carl-Henrik Heldin"
Visar resultat 11 - 15 av 32 avhandlingar innehållade orden Carl-Henrik Heldin.
11. Molecular mechanisms for activation of non-canonical TGFβ pathways and their importance during prostate cancer progression
Sammanfattning : Prostate cancer is the most common invasive cancer diagnosed in men and a major and growing health problem in Western countries. Deregulation of different pathways has been implicated in progression of prostate cancer, namely nuclear factor kappa enhancer binding protein (NF-κB), transforming growth factor β (TGFβ), phosphoinositide 3ʹ-kinase/AKT (PI3K/AKT) and Src kinase pathways. LÄS MER
12. Regulation of TGF-β/Smad Signaling Through Smad Interacting Proteins
Sammanfattning : Transforming growth factor-β (TGF-β) superfamily members are multi-functional regulators of cell fate. These factors signal by binding to a limited number of highly conserved transmembrane type I and type II serine/threonine kinase receptors. These receptors initiate signals into the cell via the Smad proteins. LÄS MER
13. Modulation of PDGF Receptor Signaling via the Phosphatase SHP-2 and the Docking Protein Gab1
Sammanfattning : x.... LÄS MER
14. T-Cell Protein Tyrosine Phosphatase, a Regulator of the PDGF Signaling Pathway
Sammanfattning : Platelet-derived growth factor (PDGF) is a potent stimulator of cell growth, survival and motility. PDGF exerts its function by binding to specific tyrosine kinase receptors, initiating receptor auotphosphorylation and initiation of specific signaling pathways that regulates the cellular response. LÄS MER
15. Combination Therapies Targeting PDGF and VEGF Signaling Pathways in Solid Tumors
Sammanfattning : Vascular endothelial growth factor (VEGF) and platelet-derived growth factor (PDGF) are independently involved in several cancer-associated mechanisms including autocrine stimulation of cancer cells, stimulation of tumor angiogenesis and regulation of interstitial fluid pressure (IFP). The scope of this thesis was to investigate the combinatory effect of anti-VEGF and anti-PDGF treatment on tumor angiogenesis and tumor IFP. LÄS MER